<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02769702</url>
  </required_header>
  <id_info>
    <org_study_id>Acthar Uveitis Study</org_study_id>
    <nct_id>NCT02769702</nct_id>
  </id_info>
  <brief_title>Open Label Study of Acthar SQ Gel Injection in Patients With Active Anterior Uveitis</brief_title>
  <official_title>Prospective Open Label Study of Acthar SQ Gel Injection in Patients With Active Anterior Uveitis Who Are Not Well Controlled With, or Intolerant of, Topical or Systemic Corticosteroids</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Washington University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Mallinckrodt</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Washington University School of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Uveitis is an acute or chronic inflammatory condition of unknown etiology. Although uveitis
      often responds adequately to topical corticosteroids, there are many patients for which this
      treatment is either inadequate or not tolerated. A patient with inadequate response to
      treatment would manifest uveitis activity by slit lamp examination determination of anterior
      chamber cellularity. Lack of tolerance of therapy commonly manifests as ocular hypertension
      (greater than 21 mmHg measured by tonometry)complicating chronic topical corticosteroid
      administration, leading to glaucoma and permanent visual loss. Moreover, systemic
      corticosteroids may be required at a dose unsafe for chronic administration. In these
      situations, an immunosuppressive medication is often added as a &quot;steroid-sparing&quot; agent. If
      and when there is clinical response to the added immunosuppressive, the oral and/or topical
      corticosteroid dose can be reduced or eliminated to avoid toxicity.

      There are several reasons for believing that Acthar might be beneficial in the treatment of
      uveitis patients. In addition to increasing adrenal production or cortisol, Acthar has
      another important mechanisms of action mediated by its binding of melanocortin receptors.
      Melanocortin down-regulates activity of B and T lymphocytes, monocytes and macrophages. In
      animal studies, melanocortin peptides down-regulate T helper cells, up-regulate T Regulatory
      cells, and decrease B lymphocyte production of B Lymphocyte Stimulator. In macrophages, there
      is down-regulation of IL-1, IL-2, INF gamma, TNF alpha, nitric oxide and adhesion molecules.
      In other cells, in addition to IL-10 upregulation (monocytes), there is down-regulation of
      VACM and ECAM (endothelial cells), prostaglandins (fibroblasts) and MCP-1 and RANTES (renal
      tubules).CNS mediation of systemic inflammation may also be down-regulated by melanocortin
      receptor binding by Acthar.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients eligible for the study will be identified by the investigators and given a copy of
      the consent form to read. Patients interested in enrolling will be screened and if eligible
      will be enrolled in the study. The screening visit and the baseline visit may occur on the
      same day. Patients enrolling will be instructed in self-administering Acthar 80 IU twice a
      week. Patients will keep an injection log which will be inspected at each visit (4, 8, and 12
      weeks). Ophthalmology data will be collected at each visit and recorded on the case report
      form by the ophthalmology technician working with the sub-investigator at the time of each
      visit. Patients will come to the Center for Clinical Studies each visit for blood draw, blood
      pressure recording, and recording of adverse events.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <start_date>June 2016</start_date>
  <completion_date type="Actual">January 6, 2017</completion_date>
  <primary_completion_date type="Actual">January 6, 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in Eye With Uveitis of Anterior Chamber Cellularity Graded From 0-4 on a Likert Scale Determined by Slit Lamp Examination</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
    <description>standard assessment of uveitis activity. Scores were assessed using a Likert scale using 0 to 4, higher score reflects more cellularity.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Baseline in Eye With Uveitis of Anterior Chamber Protein Graded 0-4 on a Likert Scale Determined by Slit Lamp Evaluation</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
    <description>standard assessment of uveitis activity. Scores were assessed using a Likert scale using 0 to 4, higher score reflects more protein.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">2</enrollment>
  <condition>Uveitis</condition>
  <arm_group>
    <arm_group_label>Intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Acthar 80 IU SC twice w eek</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Acthar</intervention_name>
    <description>Acthar 80 IU SC twice a week</description>
    <arm_group_label>Intervention</arm_group_label>
    <other_name>Acthar Gel</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Active anterior uveitis requiring oral and/or topical corticosteroid therapy

        Exclusion Criteria:

          -  Uncontrolled diabetes

          -  Uncontrolled glaucoma

          -  HIV infection or other infection for which corticosteroid therapy contraindicated

          -  Contraindication to ACTHAR

          -  Scleroderma

          -  Osteoporosis

          -  Ocular herpes simplex

          -  Systemic fungal infection

          -  Recent surgery

          -  Uncontrolled hypertension
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Richard D Brasington, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Washington U Rheumatology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Washington University in St. Louis</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2018</verification_date>
  <study_first_submitted>May 9, 2016</study_first_submitted>
  <study_first_submitted_qc>May 10, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 12, 2016</study_first_posted>
  <results_first_submitted>September 25, 2018</results_first_submitted>
  <results_first_submitted_qc>September 25, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">October 1, 2018</results_first_posted>
  <last_update_submitted>September 25, 2018</last_update_submitted>
  <last_update_submitted_qc>September 25, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">October 1, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Uveitis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Uveitis</mesh_term>
    <mesh_term>Uveitis, Anterior</mesh_term>
    <mesh_term>Iridocyclitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adrenocorticotropic Hormone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Acthar 80 IU</title>
          <description>Acthar 80 IU SC twice week</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Acthar 80 IU</title>
          <description>Acthar 80 IU SC twice week</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="2"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Eye With Uveitis of Anterior Chamber Cellularity Graded From 0-4 on a Likert Scale Determined by Slit Lamp Examination</title>
        <description>standard assessment of uveitis activity. Scores were assessed using a Likert scale using 0 to 4, higher score reflects more cellularity.</description>
        <time_frame>Baseline and 12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Acthar 80 IU</title>
            <description>Acthar 80 IU SC twice week</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Eye With Uveitis of Anterior Chamber Cellularity Graded From 0-4 on a Likert Scale Determined by Slit Lamp Examination</title>
          <description>standard assessment of uveitis activity. Scores were assessed using a Likert scale using 0 to 4, higher score reflects more cellularity.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5" spread="0.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 Weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.25" spread="1.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Baseline in Eye With Uveitis of Anterior Chamber Protein Graded 0-4 on a Likert Scale Determined by Slit Lamp Evaluation</title>
        <description>standard assessment of uveitis activity. Scores were assessed using a Likert scale using 0 to 4, higher score reflects more protein.</description>
        <time_frame>Baseline and 12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Acthar 80 IU</title>
            <description>Acthar 80 IU SC twice week</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Baseline in Eye With Uveitis of Anterior Chamber Protein Graded 0-4 on a Likert Scale Determined by Slit Lamp Evaluation</title>
          <description>standard assessment of uveitis activity. Scores were assessed using a Likert scale using 0 to 4, higher score reflects more protein.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" spread="NA">Score could not be determined for 1 of the 2 participants.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 Weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0" spread="1.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Acthar 80 IU</title>
          <description>Acthar 80 IU SC twice week</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>This study was prematurely terminated, only 2 participants enrolled. Although results are reported they should be interpreted with caution due to small sample size.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Richard Brasington MD</name_or_title>
      <organization>Washington University School of Medicine</organization>
      <phone>314-454-7255</phone>
      <email>rbrasing@wustl.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

